Philadelphiachromosomepositive acute lymphoblastic leukemia treated with imatinib in
Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphiachromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL 1 methodologies by Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, Silja Röttgers, Jeremy Hancock, Vaskar Saha, Anders Castor, Hans O. Madsen, Virginie Gandemer, Hélène Cavé, Veronica Leoni, Rolf Köhler, Giulia M. Ferrari, Kirsten Bleckmann, Rob Pieters, Vincent van der Velden, Jan Stary, Jan Zuna, Gabriele Escherich, Udo zur Stadt, Maurizio Aricò, Valentino Conter, Martin Schrappe, Maria Grazia Valsecchi, and Andrea Biondi haematol Volume 103(1): 107 -115 December 31, 2017 © 2018 by Ferrata Storti Foundation
Es. Ph. ALL treatment schema and MRD results. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
Event-free survival and cumulative incidence of relapse according to IG/TR MRD levels. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
Distribution of patients according to IG/TR MRD levels at TP 1 and TP 2. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
Event-free survival and cumulative incidence of relapse according to BCR/ABL 1 MRD levels. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
MRD detection by methodology at each time point. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
Overall concordance of IG/TR vs. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
MRD in discordant cases. Giovanni Cazzaniga et al. Haematologica 2018; 103: 107 -115 © 2018 by Ferrata Storti Foundation
- Slides: 8